Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + docetaxel + doxorubicin + nab-paclitaxel + pertuzumab + trastuzumab
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
A combination chemotherapy and targeted therapy regimen for HER2-positive breast cancer. This regimen combines four cytotoxic agents (cyclophosphamide, docetaxel, doxorubicin, and nab-paclitaxel) with two HER2-targeted monoclonal antibodies (pertuzumab and trastuzumab). The dual HER2 blockade provided by pertuzumab and trastuzumab targets different domains of the HER2 receptor, while the chemotherapy agents work through different mechanisms to kill rapidly dividing cells.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on cyclophosphamide + docetaxel + doxorubicin + nab-paclitaxel + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + docetaxel + doxorubicin + nab-paclitaxel + pertuzumab + trastuzumab.